


Real-World Experience with Gilteritinib Maintenance Following Allogeneic Transplantation in Relapsed/Refractory AML Patients Harboring *FLT3* Mutations


Yun-Tzu Lin^{1, 2}, Xavier Cheng-Hong Tsai¹, Feng-Ming Tien¹, Yuan-Yeh Kuo³, Mei-Hsuan Tseng³, Jia-Hau Liu⁴, Bor-Sheng Ko^{1,3,4}, Chieh-Lung Cheng¹, Sheng-Chieh Chou¹, Ming-En Lin¹, Chien-Chin Lin⁵, Ming-Kai Chuang⁵, Ming Yao¹, Hwei-Fang Tien^{1,6}, Hsin-An Hou^{1,7}, Wen-Chien Chou¹

Supplementary Figure 1. Overall survival (A) and relapse-free survival (B) of patients with or without pre-HSCT MRD.

(A)




(B)




Supplementary Figure 2. Overall survival (A) and relapse-free survival (B) of patients with or without post-HSCT MRD.

(A)




(B)




Supplementary Figure 3. Overall survival (A) and relapse-free survival (B) of patients with or without cGvHD.

(A)




(B)




Supplementary Figure 4. Overall survival (A) and relapse-free survival (B) of patients without pre-HSCT MRD who received post-HSCT gilteritinib maintenance or not.

(A)




(B)



Supplementary Figure 5. Overall survival (A) and relapse-free survival (B) of patients without post-HSCT MRD who received post-HSCT gilteritinib maintenance or not.

(A)



(B)

